Compare INSG & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSG | CRBU |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.1M | 192.4M |
| IPO Year | 2000 | 2021 |
| Metric | INSG | CRBU |
|---|---|---|
| Price | $10.52 | $1.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $15.33 | $10.75 |
| AVG Volume (30 Days) | 448.1K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $313,832,000.00 | N/A |
| Revenue This Year | $16.21 | $1.63 |
| Revenue Next Year | $13.28 | $10.93 |
| P/E Ratio | $15.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.28 | $1.04 |
| 52 Week High | $21.90 | $3.53 |
| Indicator | INSG | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 32.70 |
| Support Level | $9.35 | $1.39 |
| Resistance Level | $12.61 | $1.73 |
| Average True Range (ATR) | 1.23 | 0.17 |
| MACD | -0.29 | -0.06 |
| Stochastic Oscillator | 16.10 | 5.67 |
Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.